Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1056/NEJMc2415105 | DOI Listing |
N Engl J Med
January 2025
University of York, York, United Kingdom.
N Engl J Med
January 2025
Integris Baptist Medical Center, Oklahoma City, OK
In patients with transplant-eligible newly diagnosed multiple myeloma, induction therapy with a quadruplet regimen prior to autologous transplant is the standard of care. The phase III IFM2020-02-MIDAS study (NCT04934475) assessed a minimal residual disease (MRD)-driven consolidation and maintenance strategy following induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD). Here, we report safety and efficacy outcomes of six 28-day cycles of IsaKRD.
View Article and Find Full Text PDFClin Exp Dermatol
January 2025
Dermatology department, Dupuytren 2 University Hospital, Limoges, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!